Skip to main content

Bristol Myers Squibb Q3 FY2026 results

  • BMY · NYSE
  • Pharmaceuticals
  • S&P 500
$63.43+1.78%Close 13 Nov 2026 · Market value $128.9B

Bristol Myers Squibb reported revenue of $13.1 billion, up 6.9% from a year earlier, net income of $2.16 billion and diluted earnings per share of $1.05 against $1.08 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).

From its quarterly report, filed 29 Oct 2026. Compiled and checked by AapWire.

Q3 FY2026 against Q3 FY2025

Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.

Bristol Myers Squibb Q3 FY2026 results against the year-ago quarter
MeasureQ3 FY2026Q3 FY2025Change
Revenue$13.07B$12.22B+6.9%
Gross profit$8.92B$8.79B+1.5%
Gross margin68.3%71.9%−3.6 pts
Operating income$2.84B$3.01B−5.4%
Operating margin21.8%24.6%−2.8 pts
Net income$2.16B$2.20B−1.8%
Diluted EPS$1.05$1.08−2.8%
Operating cash flow$4.18B$6.31B−33.8%
Capital expenditure$344.0M$320.0M+7.5%
Free cash flow$3.84B$5.99B−36.0%

Operating KPIs for the quarter

Bristol Myers Squibb operating KPIs, Q3 FY2026
KPIQ3 FY2026Change on a year
International revenues$4.0Bup 2.6%
Gross product sales$18.0Bdown 20.1%
Net product sales$12.6Bup 6.4%
Growth Portfolio revenue$7.7Bup 11.7%
Legacy Portfolio revenue$5.4Bup 0.9%
Eliquis revenue$4.7Bup 25.2%
Opdivo revenue$2.4Bdown 6.2%
Orencia revenue$983.0Mup 2.0%
Yervoy revenue$793.0Mup 7.3%
Reblozyl revenue$750.0Mup 22.0%
Breyanzi revenue$526.0Mup 46.5%
Alliance and other revenues$463.0Mup 24.5%
Camzyos revenue$420.0Mup 41.9%
Opdualag revenue$367.0Mup 22.7%
Opdivo Qvantig revenue$334.0Mup 398.5%
Revlimid revenue$303.0Mdown 47.3%
Zeposia revenue$168.0Mup 4.3%
Pomalyst/Imnovid revenue$130.0Mdown 80.7%
Sotyktu revenue$100.0Mup 25.0%
Alliance revenues$95.0Mdown 24.0%

Earlier quarters

Bristol Myers Squibb results, last eight filed quarters
QuarterPeriod endRevenueChange on a yearDiluted EPS
Q3 FY202630 Sep 2026$13.07B+6.9%$1.05
Q2 FY202630 Jun 2026$12.97B+5.7%$1.62
Q1 FY202631 Mar 2026$11.49B+2.6%$1.31
Q4 FY202531 Dec 2025$12.50B+1.3%$0.53
Q3 FY202530 Sep 2025$12.22B+2.8%$1.08
Q2 FY202530 Jun 2025$12.27B+0.6%$0.64
Q1 FY202531 Mar 2025$11.20B−5.6%$1.20
Q4 FY202431 Dec 2024$12.34B+7.5%$0.04

More on Bristol Myers Squibb: financial statements · revenue · earnings per share

BMY's results, as they are filed.

Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.